TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15371002

Group type: EXPERIMENTAL
Intervention: Medial compartment osteoarthritic knees
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy knees
Number of subjects: 18

Group type: COMPARATOR
Intervention: Polyethylene and methacrylate cement
Number of subjects: 18
Study: 12182258

Group type: EXPERIMENTAL
Intervention: IV ramosetron 0.15 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IV ramosetron 0.3 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IV ramosetron 0.6 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10448289

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (TAM) 20 mg daily for 2 years
Number of subjects: 596

Group type: COMPARATOR
Intervention: TAM plus one cycle of low-dose, short-term chemotherapy
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: p53 mutations within the L2/L3 domains
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: p53 mutations in the L2/L3 domains
Number of subjects: 596
Study: 8561485

Group type: EXPERIMENTAL
Intervention: Low-fat butter (41% fat)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Regular butter (82% fat)
Number of subjects: 75
Study: 2651100

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with absolute alcohol (Asaki's method)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional treatment (blood transfusions, antacids, cimetidine, pirenzepine)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 145
Study: 373100

Group type: EXPERIMENTAL
Intervention: 250 mg tienilic acid
Number of subjects: 8

Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 8
Study: 30789873

Group type: EXPERIMENTAL
Intervention: Customized 3D-printed AFO
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prefabricated AFO
Number of subjects: 60
Study: 28326653

Group type: EXPERIMENTAL
Intervention: CBASP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ESC
Number of subjects: 60
Study: 25837532

Group type: EXPERIMENTAL
Intervention: 250ppm fluoride dentifrice
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 1150ppm fluoride dentifrice
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 1426ppm fluoride dentifrice
Number of subjects: 62

Group type: COMPARATOR
Intervention: No fluoride dentifrice
Number of subjects: 62
Study: 24849193

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) fixed-dose combination tablet
Number of subjects: 41
Study: 22999396

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400μg
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study: 19939303

Group type: EXPERIMENTAL
Intervention: Being with Dying: Professional Training Program in Contemplative End‐of‐Life Care (BWD)
Number of subjects: 95
Study: 17543781

Group type: EXPERIMENTAL
Intervention: 1.5 mg everolimus
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: 3 mg everolimus
Number of subjects: 634

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 634
Study: 15480108

Group type: EXPERIMENTAL
Intervention: Aldosterone inhibitor (amiloride and hydrochlorothiazide)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Extra amiloride
Number of subjects: 90
Study: 11707879

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10200704

Group type: EXPERIMENTAL
Intervention: Topically applied mesalazine 5%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Topically applied clobetasol propionate 0.05%
Number of subjects: 25
Study: 8311218

Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tegaderm dressing with EMLA cream
Number of subjects: 60
Study: 2571116

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 6

Group type: COMPARATOR
Intervention: Clonidine-desipramine combination
Number of subjects: 6
Study: 778302

Group type: EXPERIMENTAL
Intervention: Live, attenuated influenza A/England/42/72 (H3N2) vaccine
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 31173118

Group type: EXPERIMENTAL
Intervention: Patient Activation Tool (PAT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standardized consultation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 200

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 200
Study: 26318350

Group type: EXPERIMENTAL
Intervention: Acellular diphtheria-tetanus-pertussis vaccine (at least three doses)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Grade 1 to Grade 4 students
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Class grades
Number of subjects: 936
Study: 26240957

Group type: EXPERIMENTAL
Intervention: Group singing therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23396206

Group type: EXPERIMENTAL
Intervention: Low-dose JX-594
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose JX-594
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: JX-594
Number of subjects: 30
Study: 21446376

Group type: EXPERIMENTAL
Intervention: Intra-arterial lidocaine (20 mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intra-arterial lidocaine
Number of subjects: 101
Study: 19540521

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ketoisocaproate as a probe after RFA
Number of subjects: 74

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with HCC
Number of subjects: 74
Study: 17679043

Group type: EXPERIMENTAL
Intervention: ramipril at 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: atenolol at 100 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 15060258

Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 29
Study: 11228370

Group type: EXPERIMENTAL
Intervention: Live attenuated measles vaccine (Hu191)
Number of subjects: 503
Study: 9553317

Group type: EXPERIMENTAL
Intervention: Pregnant women (examined three times in each trimester)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Labored women (examined three times, once in each stage of delivery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-pregnant women
Number of subjects: 60
Study: 8067495

Group type: EXPERIMENTAL
Intervention: 40-60 mg/day of fluoxetine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 20 mg/day of fluoxetine plus 300-600 mg/day of lithium
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 20 mg/day of fluoxetine plus 25-50 mg/day of desipramine
Number of subjects: 41
Study: 3072923

Group type: EXPERIMENTAL
Intervention: 0.3% norfloxacin
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.3% tobramycin
Number of subjects: 120
Study: 31743177

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 35

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Baseline to Trendelenburg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Surgery end compared to baseline
Number of subjects: 35
Study: 29972593

Group type: EXPERIMENTAL
Intervention: Speed-of-processing training (SOPT)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Attention control (solving computerized crossword puzzles)
Number of subjects: 351
Study: 27782758

Group type: EXPERIMENTAL
Intervention: Breastfeeding education and support program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study: 25180722

Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Increasing insulin dose
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control patients (conventional therapy)
Number of subjects: 104
Study: 23271777

Group type: EXPERIMENTAL
Intervention: Active treatment for clinically localized prostate cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 0
Study: 19331675

Group type: EXPERIMENTAL
Intervention: Usual care plus Depression Care for People with Cancer
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study: 17447116

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg once daily for 1 year
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no pharmacotherapy)
Number of subjects: 17
Study: 15464332

Group type: EXPERIMENTAL
Intervention: QT variability (QTVN)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: QT variability (QTVI)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curves for QTVN
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curves for QTVI
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Cox regression for QTVN
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Cox regression for QTVI
Number of subjects: 817
Study: 12269652

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428

Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 428
Study: 9851950

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units, single intravenous infusion)
Number of subjects: 11712

Group type: COMPARATOR
Intervention: Control (no thrombolytic therapy)
Number of subjects: 11712
Study: 7989941

Group type: EXPERIMENTAL
Intervention: 175 mg/m2 of Taxol over 24 hours
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: 135 mg/m2 of Taxol over 24 hours
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Taxol administered as a 3-hour infusion
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Taxol administered as a 24-hour infusion
Number of subjects: 391

Group type: COMPARATOR
Intervention: 24-hour infusion
Number of subjects: 391
Study: 2927639

Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lisuride + low dose levodopa
Number of subjects: 90

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 90
Study: 31623474

Group type: EXPERIMENTAL
Intervention: strain-based ANN model
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: full feature ANN model
Number of subjects: 204

Group type: COMPARATOR
Intervention: full feature logistic regression model
Number of subjects: 204
Study: 30633891

Group type: EXPERIMENTAL
Intervention: Impact-resistant lenses
Number of subjects: 114
Study: 28007576

Group type: EXPERIMENTAL
Intervention: Rifaximin-EIR (400 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26423649

Group type: COMPARATOR
Intervention: Ongoing triple therapy (OT)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted protease inhibitor monotherapy (PI-mono)
Number of subjects: 587
Study: 23494869

Group type: EXPERIMENTAL
Intervention: Telephone counseling to support physical activity (n=106)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Contact control (n=86)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: At least 150 min/week of PA at both 3 and 6 months
Number of subjects: 192
Study: 21712474

Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 133065
Study: 19142802

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison of SA technology and ELISA for IL-8
Number of subjects: 12
Study: 17942465

Group type: EXPERIMENTAL
Intervention: Antenatal care program 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antenatal care program 2
Number of subjects: 0
Study: 14749158

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (150 mg twice daily)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study: 11257560

Group type: EXPERIMENTAL
Intervention: RAD 0.035 mg/kg (2.5 mg maximum)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RAD 0.10 mg/kg (7.5 mg maximum)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RAD (both doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RAD (higher dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RAD co-administration with CsA
Number of subjects: 20
Study: 9278800

Group type: EXPERIMENTAL
Intervention: Microvisc
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healon
Number of subjects: 100
Study: 8052810

Group type: EXPERIMENTAL
Intervention: pivmecillinam
Number of subjects: 59

Group type: COMPARATOR
Intervention: cotrimoxazole
Number of subjects: 59
Study: 3566234

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 172

Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 172
Study: 29741531

Group type: EXPERIMENTAL
Intervention: Physical fitness training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation (control group)
Number of subjects: 0
Study: 26612703

Group type: EXPERIMENTAL
Intervention: TrueCPR
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CPR‐Ezy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: iCPR
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard BLS
Number of subjects: 140
Study: 24029624

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 257
Study: 23719547

Group type: EXPERIMENTAL
Intervention: Calcium (600 mg) plus Vitamin D3 (200 IU) supplementation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 19449238

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 18444444

Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dronabinol (20 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16803489

Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP)
Number of subjects: 60
Study: 12768254

Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (MRA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional catheter angiography (CCA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of MRA and CCA
Number of subjects: 19
Study: 11503995

Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Super‐EBA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dentin-bonded resin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 60
Study: 9169179

Group type: EXPERIMENTAL
Intervention: Infertile women
Number of subjects: 413

Group type: COMPARATOR
Intervention: Fertile women (control group)
Number of subjects: 413
Study: 8458113

Group type: EXPERIMENTAL
Intervention: fosinopril 10 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: fosinopril 20 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: fosinopril 40 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: fosinopril (all dosages)
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 3532972

Group type: EXPERIMENTAL
Intervention: Sphincter-saving resection
Number of subjects: 413

Group type: COMPARATOR
Intervention: Abdominoperineal resection
Number of subjects: 413
Study: 28238045

Group type: EXPERIMENTAL
Intervention: AIPCW estimator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three anti-HIV regimens
Number of subjects: 0
Study: 26654751

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (CAFAP)
Number of subjects: 56
Study: 24402825

Group type: EXPERIMENTAL
Intervention: Micronized curcumin (500 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Liquid micellar curcumin (500 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Native curcumin (500 mg)
Number of subjects: 23
Study: 22039932

Group type: EXPERIMENTAL
Intervention: Coeliac School educational programme (n = 54)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care (control group, n = 52)
Number of subjects: 106
Study: 20022464

Group type: EXPERIMENTAL
Intervention: Fruit consumption
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Vegetable consumption
Number of subjects: 77
Study: 18554243

Group type: EXPERIMENTAL
Intervention: Interferon-alpha tailored treatment (5 million units thrice weekly for a median of 10 months, range 6-24 months)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group (Interferon-alpha 5 million units thrice weekly for 6 months)
Number of subjects: 374
Study: 15782295

Group type: EXPERIMENTAL
Intervention: dTpa-IPV (Boostrix Polio)
Number of subjects: 770

Group type: COMPARATOR
Intervention: DTPa-IPV (Infanrix IPV)
Number of subjects: 770

Group type: COMPARATOR
Intervention: dTpa + IPV (Boostrix + Imovax Polio)
Number of subjects: 770
Study: 11487307

Group type: EXPERIMENTAL
Intervention: Pranlukast hydrate (225.5 mg), twice a day for 1 week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9596003

Group type: EXPERIMENTAL
Intervention: 3,000-lux light for 60 minutes
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control subjects (self-regulated eye opening)
Number of subjects: 7
Study: 7810780

Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonoperative treatment (Group I)
Number of subjects: 36
Study: 2902813

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.01 mg/kg) after lormetazepam (0.06 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.01 mg/kg) after flunitrazepam (0.03 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ro 15‐1788 (0.01 mg/kg) after placebo
Number of subjects: 18
Study: 1392698

Group type: COMPARATOR
Intervention: Cyclical estrogen-progestagen replacement treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cyclical estrogen-progestagen replacement treatment plus nandrolone decanoate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (Cyclical estrogen-progestagen replacement treatment and Cyclical estrogen-progestagen replacement treatment plus nandrolone decanoate)
Number of subjects: 36
Study: 637286

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined acupuncture-analgesia
Number of subjects: 0
Study: 31071541

Group type: EXPERIMENTAL
Intervention: Clinical trial for preschool onset depression
Number of subjects: 35

Group type: COMPARATOR
Intervention: Community-recruited children
Number of subjects: 35
Study: 28890922

Group type: EXPERIMENTAL
Intervention: Inverted Classroom (IC) method
Number of subjects: 299

Group type: COMPARATOR
Intervention: Traditional teaching method (control)
Number of subjects: 299
Study: 26007680

Group type: EXPERIMENTAL
Intervention: OHIP-TMDs
Number of subjects: 76
Study: 23509019

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 200 μg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 100 μg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl (both doses)
Number of subjects: 160
Study: 21890580

Group type: EXPERIMENTAL
Intervention: Shock-absorbing flooring (8.3 mm thick vinyl floor covering with polyvinyl chloride foam backing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard flooring (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shock-absorbing flooring
Number of subjects: 0
Study: 19648781

Group type: EXPERIMENTAL
Intervention: 0.1% retinol (ROL)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Topical application of ROL-containing product
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tryptophan fluorescence spectroscopy in active-agent-treated group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study: 17341509

Group type: EXPERIMENTAL
Intervention: Thoracic spine thrust mobilization/manipulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thoracic spine nonthrust mobilization/manipulation
Number of subjects: 60
Study: 15461622

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m2
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bortezomib alone or in combination with dexamethasone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 54
Study: 11916359

Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg (n = 85)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg (n = 91)
Number of subjects: 176
Study: 9773694

Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 1874

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 1874
Study: 7848395

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every day
Number of subjects: 34

Group type: COMPARATOR
Intervention: H2RA (ranitidine 150 mg twice daily or famotidine 20 mg twice daily)
Number of subjects: 34
Study: 2904881

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy with severe hypoglycemic episodes
Number of subjects: 0
Study: 30517065

Group type: EXPERIMENTAL
Intervention: 37.5% hydrogen peroxide (HP) gel
Number of subjects: 33

Group type: COMPARATOR
Intervention: 6% hydrogen peroxide (HP) gel
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (37.5% HP and 6% HP)
Number of subjects: 33